Last reviewed · How we verify
PRFM treatment
PRFM treatment is a Regenerative medicine / Autologous cell therapy Biologic drug developed by The New York Eye & Ear Infirmary. It is currently in Phase 3 development for Corneal epithelial defects and ocular surface disease.
PRFM (platelet-rich fibrin matrix) treatment uses autologous platelet-derived growth factors and fibrin scaffolding to promote tissue regeneration and healing.
PRFM (platelet-rich fibrin matrix) treatment uses autologous platelet-derived growth factors and fibrin scaffolding to promote tissue regeneration and healing. Used for Corneal epithelial defects and ocular surface disease.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PRFM treatment |
|---|---|
| Sponsor | The New York Eye & Ear Infirmary |
| Drug class | Regenerative medicine / Autologous cell therapy |
| Modality | Biologic |
| Therapeutic area | Ophthalmology / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
PRFM is a regenerative medicine approach that concentrates platelets and fibrin from the patient's own blood to create a bioactive matrix. This matrix releases growth factors (PDGF, VEGF, FGF, TGF-β) that stimulate angiogenesis, cell proliferation, and tissue remodeling. The fibrin scaffold provides structural support for new tissue formation and is gradually resorbed as healing progresses.
Approved indications
- Corneal epithelial defects and ocular surface disease
Common side effects
- Infection at application site
- Inflammation
- Delayed healing
Key clinical trials
- Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis (PHASE1)
- Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) (PHASE3)
- Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation (PHASE1, PHASE2)
- Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRFM treatment CI brief — competitive landscape report
- PRFM treatment updates RSS · CI watch RSS
- The New York Eye & Ear Infirmary portfolio CI
Frequently asked questions about PRFM treatment
What is PRFM treatment?
How does PRFM treatment work?
What is PRFM treatment used for?
Who makes PRFM treatment?
What drug class is PRFM treatment in?
What development phase is PRFM treatment in?
What are the side effects of PRFM treatment?
Related
- Drug class: All Regenerative medicine / Autologous cell therapy drugs
- Manufacturer: The New York Eye & Ear Infirmary — full pipeline
- Therapeutic area: All drugs in Ophthalmology / Regenerative Medicine
- Indication: Drugs for Corneal epithelial defects and ocular surface disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing